Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Abiomed About Unlawful Promotion Of Impella Cardiac Pump

This article was originally published in The Gray Sheet

Executive Summary

FDA says Abiomed is promoting its top-selling Impella 2.5 cardiac pump for unapproved uses, and sent a warning letter to the firm June 10.
Advertisement

Related Content

Regulatory News In Brief
News In Brief
Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial
Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial

Topics

Advertisement
UsernamePublicRestriction

Register

MT030304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel